Loading clinical trials...
Loading clinical trials...
EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Haukeland University Hospital
Bergen, Norway
University Hospital, Akershus
Lørenskog, Norway
Oslo University Hospital, Rikshospitalet
Oslo, Norway
Oslo University Hospital, Ullevål
Oslo, Norway
University Hospital Northern Norway
Tromsø, Norway
St. Olavs hospital
Trondheim, Norway
Start Date
May 1, 2024
Primary Completion Date
December 31, 2028
Completion Date
February 28, 2029
Last Updated
February 19, 2026
450
ESTIMATED participants
Atorvastatin 40mg
DRUG
Placebo
DRUG
Atorvastatin 20mg
DRUG
Lead Sponsor
St. Olavs Hospital
Collaborators
NCT03432286
NCT05207865
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06004388